arrow
R

Rodney Dawson

University of Cape Town Lung Institute
H指数:47
被引数:7,180

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

替诺福韦-拉米夫定-多替拉韦在初治和病毒学抑制个体中,从基于NNRTI的方案转换后的病毒学结局:一项13个中心的观察性分析

2025-07-011
OAAI
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

4个月利福喷丁为基础的结核病治疗方案在糖尿病患者中的疗效与安全性

2025-03-010
OA
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Bedaquiline-pretomanid-莫西沙星-吡嗪酰胺治疗药物敏感性和耐药性肺结核: 一项2c期,开放标签,多中心,部分随机对照试验

2024-09-016
OAAI
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With Human Immunodeficiency Virus From 6 Countries
2024-05-131
PRE
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis
2024-03-110
OAAI
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

肺结核患者大剂量利福平的药物相互作用潜力

2023-10-183
OAAI
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832

健康成人的I期单次递增剂量和食物效应研究以及肺结核患者的I/IIa期多次递增剂量研究,以评估OPC-167832的药代动力学,杀菌活性,耐受性和安全性

2023-06-155
OAAI
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis

耐利福平和耐多药结核病家庭接触者中结核感染和疾病的1年发病率

2023-05-253
OA
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
2023-05-152
OA
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With HIV (S31/A5349)
2022-08-3016
OA
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
2021-04-0135
OAAI